Genetic variants of glutamate receptor gene family in Taiwanese Kawasaki disease children with coronary artery aneurysms by unknown
Cell & Bioscience
Lin et al. Cell & Bioscience 2014, 4:67
http://www.cellandbioscience.com/content/4/1/67RESEARCH Open AccessGenetic variants of glutamate receptor gene
family in Taiwanese Kawasaki disease children
with coronary artery aneurysms
Ying-Ju Lin1,2, Jeng-Sheng Chang3, Xiang Liu4, Hsinyi Tsang4, Ting-Hsu Lin1, Chiu-Chu Liao1, Shao-Mei Huang1,
Wen- Kuei Chien5,6, Jin-Hua Chen5,6, Jer-Yuarn Wu2,7, Chien-Hsiun Chen2,7, Li-Ching Chang7, Cheng-Wen Lin8,
Tsung-Jung Ho2,9,10 and Fuu-Jen Tsai1,2,11*Abstract
Background: Patients with Kawasaki disease (KD), a pediatric systemic vasculitis, may develop coronary artery
aneurysm (CAA) as a complication. To investigate the role of glutamate receptors in KD and its CAA development,
we performed genetic association studies.
Methods and results: We examined the whole family of glutamate receptors by genetic association studies in a
Taiwanese cohort of 262 KD patients. We identified glutamate receptor ionotropic, kainate 1 (GRIK1) as a novel
susceptibility locus associated with CAA formation in KD. Statistically significant differences were noted for factors
like fever duration, 1st Intravenous immunoglobulin (IVIG) used time (number of days after the first day of fever)
and the GRIK1 (rs466013, rs425507, and rs38700) genetic variants. This significant association persisted even after
using multivariate regression analysis (Full model: for rs466013: odds ratio =2.12; 95% CI =1.22-3.65; for rs425507:
odds ratio =2.16; 95% CI =1.26-3.76; for rs388700: odds ratio =2.16; 95% CI =1.26-3.76).
Conclusions: We demonstrated that GRIK1 polymorphisms are associated CAA formation in KD, even when adjusted
for fever duration and IVIG used time, and may also serve as a genetic marker for the CAA formation in KD.
Keywords: KD, GRIK1, Single nucleotide polymorphism, CAABackground
Patients with Kawasaki disease (KD), an acute systemic vas-
culitis, may develop coronary artery aneurysm (CAA) as a
complication. KD is one of the leading causes of acquired
cardiovascular diseases in childhood. Infectious agents,
host immune dysregulation, and genetic susceptibility
are thought to be responsible for the development of
KD and its related complications [1-3]. However, the
pathological mechanisms underlying KD remain to be
elucidated.
Numerous genome-wide association studies have
been conducted to identify host cellular genes that
affect KD susceptibility [4-14] in the European, Japanese,
Korean, and Taiwanese populations. In the European* Correspondence: d0704@mail.cmuh.org.tw
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unless otherwise stated.population [11,13], no common SNPs have been identified
as susceptibility loci for European KD. However, a com-
mon SNP (rs2233152; MIA gene) was observed in the
European, Japanese, and Taiwanese populations [9-11].
Common gene SNPs among Asians including Japanese,
Taiwanese, and Korean populations have also been ob-
served [4,6,9,10,12,14,15]. Six SNPs, namely, rs2736340
(BLK), rs2618479 (BLK), rs6993775 (BLK), rs10401344
(ITPKC), rs2233152 (MIA), and rs4813003 (CD40) have
been observed in both Japanese and Taiwanese popula-
tions [9,10] (Additional files 1 and 2). These studies
suggest that genes involved in the immune-regulatory
responses and cardiovascular-related pathogenesis may
contribute to KD susceptibility.
Glutamate receptors were initially demonstrated to play
important roles in excitatory neurotransmission in the
brain and interneuronal communication [16]. Based on
their different activation mechanisms, glutamate receptors. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ceptors (iGluRs) and metabotropic glutamate receptors
(mGluRs). The human genome is known to contain at
least 16 iGluRs and 8 mGluRs. Based on their agonist
binding and electrophysiological properties, iGluRs can be
classified to 3 groups: alpha-amino-3-hydroxy-5-methyl-
4-isoxazole (AMPA), N-methyl-D-aspartate (NMDA), and
kainate (KA) receptors. Genetic mutations in glutamate
receptors are associated with a number of human diseases
including autism, Huntington’s disease and Parkinson’s
disease [17,18]. In addition, glutamate receptors have been
found to influence autoantigen/antibody interactions and
multiple sclerosis. GluR3 (GRIA3) is known to act as
an autoantigen in Rasmussen’s encephalitis, suggesting
a strong link between glutamate receptors and auto-
immune interaction in certain degenerative diseases [19].
The regulation of glutamate receptor binding activity can
reduce central nervous system (CNS) inflammation, apop-
tosis, and axonal damage [20]. In addition, glutamate
receptors have also been implicated in cardiovascular
diseases [21]. Glutamate receptor 1 (GluR1), an AMPA
receptor subtype, can mediate the regulation of platelet
activation through glutamate and GluR1 knockout
mice develop in vivo thrombosis after a prolonged time
[22]. The activation of GluR1 may contribute to the
development of cardiovascular disease via accelerating
thrombus formation.
Endothelial cells are principal targets for ischemic
free-radical injury. Glutamate receptors are known to
prevent nitric oxide-induced vascular injury [23]. On the
other hand, activation of certain glutamate receptors was
demonstrated to be a potential strategy for disrupting
angiogenesis [24]. Coronary artery damage in KD is strongly
associated with endothelial cell dysfunction [25]. Additional
evidence suggests that glutamate receptors may influence
KD pathogenesis [26,27].
To explore the role of glutamate receptors in KD de-
velopment, we investigated the entire family of glutam-
ate receptors by performing genetic association studies
on a Taiwanese cohort of 262 KD patients. Our study iden-
tified glutamate receptor ionotropic, kainate 1 (GRIK1) as a
novel susceptibility locus on 21q21.3. To our knowledge,
this is the first instance to screen the glutamate receptor
family for the association between genetic variants of glu-
tamate receptors and CAA formation in KD.
Results
Genetic association study of the glutamate receptor gene
family in Taiwanese KD children and controls
To identify KD susceptibility genes, a total of 53 SNPs of
16 genes within the glutamate receptor gene family in-
cluding GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIA1,
GRIA2, GRIA4, GRM1, GRM2, GRM3, GRM4, GRM5,
GRM6, GRM7, and GRM8 genes were genotyped in 262Taiwanese KD children and in 1107 healthy people from
the general population of Taiwan who were Han Chinese
ethnic background for the SNP association study (Table 1).
No significant differences were found between these 2
groups, suggesting that the glutamate receptor family
genes may not contribute to KD susceptibility.
GRIK1 genetic polymorphisms may be related to
KD-associated CAA complications
To examine the role of glutamate receptors in KD-
associated CAA complications, we analyzed the correl-
ation between KD children and the whole glutamate
gene family. As shown in Table 2, the genotype distri-
butions (dominant model) of 6 glutamate gene SNPs
were statistically different between these 2 groups (p <0.05).
These SNPs were rs466013, rs425507, rs388700, rs402280,
rs17104835 and rs712723. Among these, 4 SNPs were
found to be located in the GRIK1 gene (p =0.007, 0.005,
0.004 and 0.022, respectively) (Additional file 1). GRIK1
consists of 18 exons and is located at 21q21.3 as shown in
Figure 1. All SNPs were in Hardy-Weinberg equilibrium
and had a successful genotyping frequency of >99%. The
linkage disequilibrium (LD) structure of this region was
also established, with 1 haplotype block determined. Four
SNPs were located in that block. To evaluate the relation-
ship among these 4 SNPs, pairwise LD analysis was per-
formed. The D’ statistics were all 1.0. Strong LD was
observed in the following 2 groups of SNPs, group1
(rs466013, rs425507, rs388700), with the r2 statistics >0.5
between every 2 SNPs in each group (data not shown).
The frequencies of the TT and TC genotypes of GRIK1
(rs466013) were significantly higher in KD patients with
CAA than those in patients without CAA (63.2% for KD
with CAA and 44.9% for KD without CAA complications;
odds ratio =2.11 [95% confidence interval (CI) =1.22-
3.65]). Similar results were also observed in rs425507,
rs388700 and rs402280. These data suggest that GRIK1
may be a potential susceptibility locus involved in the de-
velopment of KD with CAA complications.
Multivariate regression analyses shows that GRIK1 genetic
polymorphisms may be related to CAA formation in KD
According to the above results, statistically significant
differences in factors associated with CAA formation in
KD were noted for the clinical characteristics including
fever duration (p <0.0001), first IVIG used time (p <0.0001;
number of days after the first day of fever), and the GRIK1
(rs466013, rs425507, rs38700, and rs402280) genetic vari-
ants (p =0.007, p =0.005, p =0.004, and p =0.022, respect-
ively) (Tables 1 and 3). To further confirm the genetic role
of GRIK1, we used multivariate regression analyses to ad-
just those potential factors (i.e., fever duration and IVIG
used time) that may affect the analysis. As shown in
Table 3, significant associations between KD with CAA
Table 1 Genotype distribution of glutamate receptor family gene SNPs in Taiwanese KD patients and controls





No. (%) No. (%) p value Odds ratio (95% CI)
rs466013 21 q21.3 29826390 GRIK1 TT + TC 507 (45.9) 131 (50.2) 0.205 1.19 (0.91-1.56)
CC 599 (54.1) 130 (49.8) 1
rs425507 21 q21.3 29827658 GRIK1 GG + GA 507(45.8) 130 (49.6) 0.265 1.17 (0.89-1.53)
AA 600 (54.2) 132 (50.4) 1
rs388700 21 q21.3 29830158 GRIK1 TT + TA 506 (45.7) 130 (49.6) 0.254 1.17 (0.89-1.53)
AA 601 (54.3) 132 (50.4) 1
rs402280 21 q21.3 29835401 GRIK1 TT + TA 424 (38.3) 116 (44.3) 0.075 1.28 (0.97-1.68)
AA 683 (61.7) 146 (55.7) 1
rs17816480 6 q16.3 101522140 GRIK2 TT + TC 201 (18.2) 48 (18.3) 0.951 1.01 (0.71-1.43)
CC 906 (81.8) 214 (81.7) 1
rs2786239 6 q16.3 101637565 GRIK2 GG + GA 186 (16.8) 45 (17.2) 0.885 1.03 (0.72-1.47)
AA 921 (83.2) 217 (82.8)
rs4840194 6 q16.3 101768497 GRIK2 CC + CT 357 (32.2) 88 (33.6) 0.677 1.06 (0.80-1.41)
TT 750 (67.8) 174 (66.4) 1
rs1310715 6 q16.3 101961427 GRIK2 TT + TC 597 (53) 133 (50.9) 0.468 0.91 (0.69-1.91)
CC 520 (47.0) 128 (49.1) 1
rs527631 1 p34.3 36844396 GRIK3 AA + AG 172 (15.5) 45 (17.6) 0.407 1.16 (0.81-1.67)
GG 935 (84.5) 210 (82.4) 1
rs476894 1 p34.3 36868682 GRIK3 GG + GA 234 (21.1) 63 (24.0) 0.305 1.18 (0.86-1.62)
AA 873 (78.9) 199 (76.0) 1
rs541671 1 p34.3 36905238 GRIK3 TT + TA 267 (24.1) 65 (25.9) 0.554 1.10 (0.80-1.51)
AA 840 (75.9) 186 (74.1) 1
rs35317705 1 p34.3 36972969 GRIK3 CC + CT 128 (11.6) 33 (12.6) 0.641 1.10 (0.73-1.66)
TT 979 (88.4) 229 (87.4) 1
rs11218005 11 q23.3 120782227 GRIK4 AA + AC 132 (11.9) 35 (13.4) 0.523 1.14 (0.76-1.70)
CC 975 (88.1) 227 (86.6) 1
rs3901285 11 q23.3 120862726 GRIK4 TT + TC 650 (58.7) 158 (60.3) 0.638 1.07 (0.81-1.41)
CC 457 (41.3) 104 (39.7) 1
rs4936566 11 q23.3 120944529 GRIK4 AA + AG 669 (60.4) 145 (55.3) 0.131 0.81 (0.62-1.06)
GG 438 (39.6) 117 (44.7) 1
rs443239 19 q13.2 42001892 GRIK5 CC + CG 289 (26.1) 64 (24.4) 0.576 0.91 (0.67-1.25)
GG 818 (73.9) 198 (75.6) 1
rs1493395 5 q33.2 153532297 GRIA1 AA + AG 565 (51.1) 125 (47.7) 0.326 0.87 (0.67-1.14)
GG 541 (48.9) 137 (52.3) 1
rs12153489 5 q33.2 153568777 GRIA1 CC + CT 1087 (98.2) 259 (98.9) 0.454 1.59 (0.47-5.39)
TT 20 (1.8) 3 (1.1) 1
rs4424038 5 q33.2 153740704 GRIA1 CC + CT 1102 (99.5) 262 (100.0) 0.276 ND
TT 5 (0.5) 0 (0.0) 1
rs17035909 4 q32.1 157247565 GRIA2 AA + AT 351 (31.7) 87 (33.3) 0.640 1.07 (0.80-1.43)
TT 756 (68.3) 175 (66.7) 1
rs17035959 4 q32.1 157302204 GRIA2 AA + AC 1075 (97.1) 255 (97.3) 0.848 1.08 (0.47-2.48)
CC 32 (2.9) 7 (2.7) 1
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rs7695870 4 q32.1 157342624 GRIA2 CC + CT 1082 (97.7) 258 (98.5) 0.460 1.49 (0.51-4.32)
TT 25 (2.3) 4 (1.5) 1
rs6855973 4 q32.1 157365463 GRIA2 AA + AT 1085 (98) 258 (98.4) 0.623 1.31 (0.45-3.83)
TT 22 (2.0) 4 (1.6) 1
rs10895875 11 q22.3 105785485 GRIA4 AA + AT 715 (64.6) 181 (69.1) 0.169 1.23 (0.92-1.64)
TT 392 (35.4) 81 (30.9) 1
rs4754136 11 q22.3 105846312 GRIA4 CC + CT 1102 (99.5) 261 (99.6) 0.877 1.18 (0.14-10.18)
TT 5 (0.5) 1 (0.4) 1
rs17104835 11 q22.3 105971356 GRIA4 CC + CT 447 (40.4) 104 (39.8) 0.839 0.97 (0.74-1.28)
TT 660 (59.6) 158 (60.2) 1
rs7750018 6 q24.3 146206595 GRM1 CC + CT 285 (25.7) 62 (23.7) 0.486 0.89 (0.65-1.23)
TT 822 (74.3) 200 (76.3) 1
rs362851 6 q24.3 146389448 GRM1 CC + CG 713 (64.4) 169 (64.5) 0.977 1.00 (0.76-1.33)
GG 394 (35.6) 93 (35.5) 1
rs2300631 6 q24.3 146428918 GRM1 AA + AG 828 (74.8) 192 (63.3) 0.613 0.92 (0.68-1.25)
GG 279 (25.2) 70 (26.7) 1
rs12023603 3 p21.2 51466999 GRM2 AA + AG 1076 (97.2) 253 (96.6) 0.583 0.81 (0.38-1.72)
GG 31 (2.8) 9 (3.4) 1
rs1983842 3 p21.2 51535259 GRM2 AA + AG 1070 (96.7) 253 (96.6) 0.940 0.97 (0.46-2.04)
GG 37 (3.3) 9 (3.4) 1
rs802441 7 q21.11 86657787 GRM3 CC + CT 1081 (97.6) 255 (97.3) 0.759 0.88 (0.38-2.04)
TT 26 (2.4) 7 (2.7) 1
rs802466 7 q21.11 86698122 GRM3 CC + CT 222 (20.0) 44 (16.8) 0.230 0.80 (0.56-1.15)
TT 885 (80.0) 218 (83.2)
rs12704286 7 q21.11 86745625 GRM3 AA + AG 364 (32.9) 91 (34.8) 0.567 1.09 (0.82-1.44)
GG 743 (67.1) 171 (65.2) 1
rs17697415 7 q21.11 86772500 GRM3 AA + AG 138 (12.5) 34 (13.0) 0.822 1.05 (0.70-1.57)
GG 969 (87.5) 228 (87.0) 1
rs1873254 6 p21.31 34058712 GRM4 AA + AG 518 (55.9) 150 (57.4) 0.096 1.26 (0.96-1.66)
GG 488 (44.1) 112 (42.6) 1
rs937039 6 p21.31 34075875 GRM4 AA + AG 1090 (98.5) 260 (99.2) 0.337 2.03 (0.47-8.83)
GG 17 (1.5) 2 (0.8) 1
rs1565361 6 p21.31 34089248 GRM4 CC + CT 503 (45.5) 117 (44.7) 0.819 0.97 (0.74-1.27)
TT 604 (54.5) 145 (55.3) 1
rs4106126 11 q14.2 88647181 GRM5 CC + CT 1093 (98.7) 256 (97.7) 0.214 0.55 (0.21-1.44)
TT 14 (1.3) 6 (2.3) 1
rs1391878 11 q14.2 88713212 GRM5 CC + CT 264 (23.9) 58 (22.1) 0.557 0.91 (0.66-1.25)
TT 843 (76.1) 204 (77.9) 1
rs12787863 11 q14.2 88810547 GRM5 AA + AG 447 (40.4) 110 (42.0) 0.634 1.07 (0.81-1.40)
GG 660 (59.6) 152 (58.0) 1
rs7126679 11 q14.2 89020677 GRM5 AA + AG 651 (58.9) 160 (61.1) 0.513 1.10 (0.83-1.44)
GG 455 (41.1) 102 (38.9) 1
rs2856354 5 q35.3 178978728 GRM6 AA + AG 1055 (95.3) 244 (93.1) 0.151 0.67 (0.38-1.16)
GG 52 (4.7) 18 (6.9) 1
Lin et al. Cell & Bioscience 2014, 4:67 Page 4 of 12
http://www.cellandbioscience.com/content/4/1/67
Table 1 Genotype distribution of glutamate receptor family gene SNPs in Taiwanese KD patients and controls
(Continued)
rs10464073 5 q35.3 178982284 GRM6 AA + AG 1056 (95.4) 244 (93.1) 0.132 0.65 (0.38-1.14)
GG 51 (4.6) 18 (6.9) 1
rs17078880 5 q35.3 178983436 GRM6 CC + CT 1089 (98.4) 258 (98.5) 0.908 1.07 (0.36-3.18)
TT 18 (1.6) 4 (1.5) 1
rs2645341 5 q35.3 178984314 GRM6 AA + AG 1087 (98.2) 258 (98.5) 0.756 1.19 (0.40-3.50)
GG 20 (1.8) 4 (1.5) 1
rs6764411 3 p26.1 7101864 GRM7 AA + AC 927 (83.8) 211 (80.5) 0.202 0.80 (0.57-1.13)
CC 179 (16.2) 51 (19.5) 1
rs17697928 3 p26.1 7326084 GRM7 AA + AG 861 (77.7) 199 (80) 0.525 0.90 (0.66-1.24)
GG 246 (22.3) 51 (19.5) 1
rs779741 3 p26.1 7541915 GRM7 AA + AC 917 (82.8) 218 (83.2) 0.886 1.03 (0.72-1.47)
CC 190 (17.2) 44 (16.8) 1
rs1354405 3 p26.1 7690304 GRM7 AA + AG 1012 (91.4) 236 (90.1) 0.491 0.85 (0.54-1.34)
GG 95 (8.6) 26 (9.9) 1
rs712723 7 q31.33 126439090 GRM8 CC + CT 698 (63.0) 174 (66.4) 0.309 1.16 (0.87-1.54)
TT 409 (37.0) 88 (33.6) 1
rs17627206 7 q31.33 126793483 GRM8 AA + AG 110 (9.9) 28 (10.7) 0.717 1.08 (0.70-1.68)
1GG 997 (90.1) 234 (89.3)
rs11563505 7 q31.33 127059729 GRM8 CC + CT 1086 (98.1) 258 (98.5) 0.687 1.25 (0.42-3.66)
TT 21 (1.9) 4 (1.5) 1
GRIK, glutamate receptor, ionotropic, kainate; GRIA, glutamate receptor, ionotropic, AMPA; GRM, glutamate receptor, metabotropic, SNP, single nucleotide
polymorphism; CI, confidence interval.
p-values were obtained by chi-square test (2 x 2 table).
Statistical significance was considered as p value <0.05.
Physical position of individual SNPs was based on the NCBI Assembly database: GRCH38 version.
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rs38700 and rs402280) genetic variants were observed
(Full model: for rs466013: odds ratio = 2.12; 95% CI =
1.22-3.65; for rs425507: odds ratio = 2.16; 95% CI = 1.26-
3.76; for rs388700: odds ratio = 2.16; 95% CI = 1.26-3.76;
for rs402280: odds ratio = 1.89; 95% CI = 1.09-3.21).
Taken together, these data suggest that the significant as-
sociation observed between CAA complications and the
presence of the GRIK1 genotypes persists even after
adjusting for the potential factors.
Discussion
Previous research from our lab suggests that the NMDA
receptor (GRIN3A) from the glutamate receptor family
may influence KD pathogenesis [26]. In this study, we
screened the entire glutamate receptor family including
the iGluRs and mGluRs (GRIK, GRIA and GRM gene fam-
ilies) and identified another member, namely GRIK1, that
may be involved in the development of KD-associated
CAA complications in Taiwanese children of Han Chinese
ethnic background. The most striking finding of this study
is that 4 GRIK1 gene variants were found to be strongly
associated with the presence of CAA in KD patients, even
in the multivariable model.Our genetic association study showed that none of the
genes of the glutamate receptor gene family including
GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIA1, GRIA2,
GRIA4, GRM1, GRM2, GRM3, GRM4, GRM5, GRM6,
GRM7, and GRM8 genes contributed to KD susceptibil-
ity. However, genetic variation of the GRIK1 locus may
potential induce susceptibility to the development of KD
with CAA complications. The significant association ob-
served between KD with CAA complications and the
GRIK1 genetic variants (rs466013, rs425507, rs38700,
and rs402280) was found to persist even after adjusting
for fever duration and first IVIG used time. These re-
sults suggest that the GRIK1 gene may be involved in
CAA formation of KD. GRIK1 polymorphisms have been
investigation for their associations with different diseases
including Juvenile absence epilepsy [28,29], schizophrenia
[30,31], alcohol dependence [32], topiramate’s effects on
heavy drinking [33,34], topiramate-induced side effects
[35], and hepatitis B virus (HBV)-related hepatocellular
carcinoma [36]. However, these GRIK1 polymorphism data
of various studies are also not absolutely consistent
and conclusive. These studies show that GRIK1 gene
may mainly contribute to neuropsychological diseases.
Glutamate is known to signal and is released by nerves,
Table 2 Association of the genetic variants of glutamate receptor family genes in Taiwanese KD children according to
the presence or absence of CAA




KD CAA- KD CAA+
No. (%) No. (%) p value Odds ratio (95% CI)
rs466013 21 q21.3 29826390 GRIK1 TT + TC 83 (44.9) 48 (63.2) 0.007 2.11 (1.22-3.65)
CC 102 (55.1) 28 (36.8) 1
rs425507 21 q21.3 29827658 GRIK1 G + GA 82 (44.1) 48 (63.2) 0.01 2.17 (1.26-3.76)
AA 104 (55.9) 28 (36.8) 1
rs388700 21 q21.3 29830158 GRIK1 TT + TA 81 (44.1) 48 (63.2) 0.004 2.20 (1.27-3.81)
AA 104 (55.9) 28 (36.8) 1
rs402280 21 q21.3 29835401 GRIK1 TT + TA 74 (39.8) 42 (55.2) 0.022 1.87 (1.09-3.21)
AA 112 (60.2) 34 (44.8) 1
rs17816480 6 q16.3 101522140 GRIK2 TT + TC 30 (16.1) 18 (23.7) 0.151 1.61 (0.84-3.11)
CC 156 (83.9) 58 (76.3) 1
rs2786239 6 q16.3 101637565 GRIK2 GG + GA 29 (15.6) 16 (21.1) 0.288 1.44 (0.73-2.85)
AA 157 (84.4) 60 (78.9) 1
rs4840194 6 q16.3 101768497 GRIK2 CC + CT 64 (34.4)) 24 (31.6) 0.660 0.88 (0.50-1.56)
TT 122 (65.6) 52 (68.4) 1
rs1310715 6 q16.3 101961427 GRIK2 TT + TC 91 (49.2) 42 (55.3) 0.373 1.28 (0.75-2.18)
CC 94 (50.8) 34 (44.7) 1
rs527631 1 p34.3 36844396 GRIK3 AA + AG 32 (17.6) 13 (17.8) 0.966 1.02 (0.50-2.07)
GG 150 (82.4) 60 (82.2) 1
rs476894 1 p34.3 36868682 GRIK3 GG + GA 45 (24.2) 18 (23.7) 0.930 0.97 (0.52-1.82)
AA 141 (75.8) 58 (76.3) 1
rs541671 1 p34.3 36905238 GRIK3 TT + TA 47 (26.1) 18 (25.3) 0.902 0.96 (0.51-1.80)
AA 133 (73.9) 53 (74.7) 1
rs35317705 1 p34.3 36972969 GRIK3 CC + CT 22 (11.8) 11 (14.5) 0.558 1.26 (0.58-2.75)
TT 164 (88.2) 65 (85.5) 1
rs11218005 11 q23.3 120782227 GRIK4 AA + AC 27 (14.5) 8 (10.5) 0.389 0.69 (0.30-1.60)
CC 159 (85.5) 68 (89.5) 1
rs3901285 11 q23.3 120862726 GRIK4 TT + TC 113 (60.7) 45 (59.2) 0.817 0.94 (0.54-1.62)
CC 73 (39.3) 31 (40.8) 1
rs4936566 11 q23.3 120944529 GRIK4 AA + AG 104 (55.9) 41 (54.0) 0.771 0.92 (0.54-1.58)
GG 82 (44.1) 35 (46.0) 1
rs443239 19 q13.2 42001892 GRIK5 CC + CG 45 (24.2) 19 (25.0) 0.890 1.04 (0.56-1.94)
GG 141 (75.8) 57 (75.0) 1
rs1493395 5 q33.2 153532297 GRIA1 AA + AG 88 (47.3) 37 (48.7) 0.840 1.06 (0.62-1.80)
GG 98 (52.7) 39 (51.3) 1
rs12153489 5 q33.2 153568777 GRIA1 TT + CT 40 (21.5) 19 (25.0) 0.539 1.22 (0.65-2.28)
CC 146 (78.5) 57 (75.0) 1
rs4424038 5 q33.2 153740704 GRIA1 TT + CT 23 (12.4) 10 (13.2) 0.861 1.07 (0.48-2.38)
CC 163 (87.6) 66 (86.8) 1
rs17035909 4 q32.1 157247565 GRIA2 AA + AT 66 (35.7) 21 (27.6) 0.210 0.69 (0.38-1.24)
TT 119 (64.3) 55 (72.4) 1
rs17035959 4 q32.1 157302204 GRIA2 CC + AC 72 (38.7) 25 (32.9) 0.376 0.78 (0.44-1.36)
AA 114 (61.3) 51 (67.1) 1
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Table 2 Association of the genetic variants of glutamate receptor family genes in Taiwanese KD children according to
the presence or absence of CAA (Continued)
rs7695870 4 q32.1 157342624 GRIA2 TT + CT 50 (26.9) 26 (34.2) 0.236 1.41 (0.80-2.51)
CC 136 (73.1) 50 (65.8) 1
rs6855973 4 q32.1 157365463 GRIA2 TT + AT 60 (33.2) 18 (24.0) 0.148 0.64 (0.34-1.18)
AA 121 (66.8) 57 (76.0) 1
rs10895875 11 q22.3 105785485 GRIA4 AA + AT 130 (69.9) 51 (67.1) 0.673 1.16 (0.58-2.30)
TT 56 (30.1) 25 (32.9) 1
rs4754136 11 q22.3 105846312 GRIA4 TT + CT 26(14.0) 5 (6.6) 0.092 0.43 (0.16-1.17)
CC 160 (86.0) 71 (93.4) 1
rs17104835 11 q22.3 105971356 GRIA4 CC + CT 66 (35.7) 38 (50) 0.032 1.80 (1.05-3.10)
TT 119 (64.3) 38 (50) 1
rs7750018 6 q24.3 146206595 GRM1 CC + CT 43 (23.1) 19 (25.0) 0.745 1.11 (0.60-2.06)
TT 143 (76.9) 57 (75.0) 1
rs362851 6 q24.3 146389448 GRM1 CC + CG 117 (62.9) 52 (68.4) 0.397 1.28 (0.72-2.25)
GG 69 (37.1) 24 (31.6) 1
rs2300631 6 q24.3 146428918 GRM1 AA + AG 135 (72.7) 57 (75.0) 0.688 1.13 (0.62-2.09)
GG 51 (27.4) 19 (25.0) 1
rs12023603 1 p21.2 51466999 GRM2 GG + AG 50 (26.9) 22 (28.9) 0.734 1.11 (0.61-2.00)
AA 136 (73.1) 54 (71.1) 1
rs1983842 1 p21.2 51535259 GRM2 GG + AG 56 (30.1)) 23 (30.2) 0.980 1.01 (0.56-1.80)
AA 130 (69.9) 53 (69.8) 1
rs802441 7 q21.11 86657787 GRM3 TT + CT 51 (27.4) 23 (30.2) 0.643 1.15 (0.64-2.06)
CC 135 (72.6) 53 (69.8) 1
rs802466 7 q21.11 86698122 GRM3 CC + CT 35 (18.8) 9 (11.8) 0.171 0.58 (0.26-1.27)
TT 151 (81.2) 67 (88.2) 1
rs12704286 7 q21.11 86745625 GRM3 AA + AG 60 (33.3) 27 (38.6) 0.435 1.26 (0.71-2.23)
GG 120 (66.7) 43 (61.4) 1
rs17697415 7 q21.11 86772500 GRM3 AA + AG 22 (11.8) 12 (15.8) 0.387 1.40 (0.65-2.99)
GG 164 (88.2) 64 (84.2) 1
rs1873254 6 p21.31 34058712 GRM4 AA + AG 105 (57.4) 43 (57.3) 0.995 1.00 (0.58-1.72)
GG 78 (42.6) 32 (42.7) 1
rs937039 6 p21.31 34075875 GRM4 GG + AG 44 (23.6) 17 (22.4) 0.823 0.93 (0.49-1.76)
AA 142 (76.4) 59 (77.6) 1
rs1565361 6 p21.31 34089248 GRM4 CC + CT 84 (45.2) 33 (43.4) 0.797 0.93 (0.54-1.60)
TT 102 (54.8) 43 (56.6) 1
rs4106126 11 q14.2 88647181 GRM5 TT + CT 43 (23.1) 18 (23.7) 0.922 1.03 (0.55-1.94)
CC 143 (76.9) 58 (76.3) 1
rs1391878 11 q14.2 88713212 GRM5 CC + CT 39 (21.0) 19 (25.0) 0.476 1.26 (0.67-2.35)
TT 147 (79.0) 57 (75.0) 1
rs12787863 11 q14.2 88810547 GRM5 AA + AG 77 (41.4) 33 (43.4) 0.763 1.09 (0.63-1.86)
GG 109 (58.6) 43 (56.6) 1
rs7126679 11 q14.2 89020677 GRM5 AA + AG 109 (59.9) 48 (64.0) 0.539 1.19 (0.68-2.08)
GG 73 (40.1) 27 (36.0) 1
rs2856354 5 q35.3 178978728 GRM6 GG + AG AA 81 (43.6) 37 (48.7) 0.448 1.23 (0.72-2.10)
105 (56.4) 39 (51.3) 1
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Table 2 Association of the genetic variants of glutamate receptor family genes in Taiwanese KD children according to
the presence or absence of CAA (Continued)
rs10464073 5 q35.3 178982284 GRM6 GG + AG 81 (43.6) 37 (48.7) 0.448 1.23 (0.72-2.10)
AA 105 (56.4) 39 (51.3) 1
rs17078880 5 q35.3 178983436 GRM6 TT + CT 51 (27.7) 20 (26.7) 0.863 0.95 (0.52-1.74)
CC 133 (72.3) 55 (73.3) 1
rs2645341 5 q35.3 178984314 GRM6 GG + AG 53 (28.5) 19 (25.0) 0.565 0.84 (0.45-1.54)
AA 133 (71.5) 57 (75.0) 1
rs6764411 3 p26.1 7101864 GRM7 CC + AC 127 (68.3) 52 (68.4) 0.982 1.01 (0.57-1.79)
AA 59 (31.7) 24 (31.6) 1
rs17697928 3 p26.1 7326084 GRM7 AA + AG 130 (69.9) 48 (63.2) 0.289 0.74 (0.42-1.29)
GG 56 (30.1) 28 (36.8) 1
rs779741 3 p26.1 7541915 GRM7 CC + AC 124 (66.7) 48 (63.2) 0.587 0.86 (0.49-1.50)
AA 62 (33.3) 28 (36.8) 1
rs1354405 3 p26.1 7690304 GRM7 GG + AG 103 (55.4) 38 (50.0) 0.428 0.81 (0.47-1.38)
AA 83 (44.6) 38 (50.0) 1
rs712723 7 q31.33 126439090 GRM8 CC + CT 115 (61.8) 59 (77.6) 0.014 2.14 (1.16-3.6)
1
rs17627206 7 q31.33 126793483 GRM8 TT AA + AG 71 (38.2) 20 (10.7) 17 (22.4) 8 (10.5) 0.957 0.98 (0.41-2.32)
GG 166 (89.3) 68 (89.5) 1
rs11563505 7 q31.33 127059729 GRM8 TT + CT 46 (24.7) 19 (25.0) 0.964 1.01 (0.55-1.88)
CC 140 (75.3) 57 (75.0) 1
Physical position of individual SNPs was based on the NCBI Assembly database: GRCH38 version.
GRIK, glutamate receptor, ionotropic, kainate; GRIA, glutamate receptor, ionotropic, AMPA; GRM, glutamate receptor, metabotropic, SNP, single nucleotide
polymorphism; CI, confidence interval.
p-values were obtained by chi-square test (2 x 2 table).
Bold italic are significant at p value <0.05.
Chr 21
29193 K
29536 K 29694 K 29941 K
GRIK1
30211 K
Figure 1 Analysis of single nucleotide polymorphisms (SNPs) and the linkage disequilibrium (LD) pattern of the GRIK1 gene. Genomic location
of SNPs present on chromosome 21q21.3. Physical position of individual SNPs was based on the NCBI Assembly database: GRCh38 version. Linkage
disequilibrium (LD) blocks in the GRIK1 gene, estimated by using HAPLOVIEW software. Pairwise D’ values (%) are indicated in squares; red indicates
linkage disequilibrium [D’ =1, logarithm of odds (LOD) ≥2].
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Table 3 Association of GRIK1 genetic polymorphisms with
CAA complications in Taiwanese KD children by
multivariate regression analysis
GRIK1 genetic polymorphisms Odds ratio 95% CI p value
Full model (adjusted by fever duration and first IVIG used time)
rs466013 2.12 1.22-3.65 0.011
rs425507 2.16 1.26-3.76 0.009
rs388700 2.16 1.26-3.76 0.009
rs402280 1.89 1.09-3.21 0.028
GRIK1, glutamate receptor, ionotropic, kainate 1; IVIG, Intravenous
immunoglobulin; CAA, Coronary artery aneurysm; CI, confidence interval.
Full model shows results from a logistic regression model including the
indicated predictors, fever duration (days) and first IVIG used time (number of
days after the first day of fever).
Bold italic are significant at p value <0.05.
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http://www.cellandbioscience.com/content/4/1/67macrophages, lymphocytes, and chondrocytes [37,38]. These
amino acids bind to iGluRs and mGluRs to regulate periph-
eral pain, release of cytokines and matrix metalloproteinases,
and immune responses [39-41]. Our studies have firstly
showed that glutamate receptors including NMDA [26] and
KA receptors are involved in the CAA complications of KD
regardless of the fever duration and first IVIG used time.
KD is a multi-systemic disorder with a possible underlying
pathology of immune-mediated vasculitis [1,42]. The vascu-
lar endothelium forms a functional barrier between the ves-
sel wall and the bloodstream. Recent studies have shown
that regulation of certain glutamate receptors may induce
the inflammation of endothelial cells, thereby mediating
pathogenesis of vascular diseases [43,44]. Although the
current therapy for KD includes high doses of aspirin in
conjunction with IVIG treatment [45], reports suggest that
this regimen cannot efficiently prevent CAA development.
In this study, we showed that the glutamate receptor
GRIK1 is significantly associated with KD with CAA
complications in Taiwanese children with Han Chinese
ethnic background. Genetic polymorphisms of the GRIK1
gene may play a role in KD pathogenesis and this mol-
ecule may serve as a therapeutic target for the KD
treatment to prevent CAA development. Children with
specific glutamate receptor genotypes related to KD
should be careful assessed for CAA status at the time
of diagnosis and monitored during the CAA develop-
ment and related cardiovascular diseases. In addition
to aspirin and IVIG therapy, the glutamate receptors




We performed a retrospective study. Individuals fulfilling
the diagnostic criteria of KD (n = 262) were identified
and enrolled into this study from the Department of
Pediatrics at China Medical University Hospital in Tai-
chung, Taiwan [46,47]. This study population has beenpreviously used for SNP analysis and KD studies
[4,10,26,48,49]. In this study, there were 164 males and
94 females with an average age at diagnosis 1.75 ±
1.61 years. All the patients were diagnosed according
to KD criteria [50]. All the patients underwent regular
echocardiography examinations at the acute stage, 2 and
6 months after onset and once a year thereafter. CAA was
identified when either the right or left coronary artery
showed a dilated diameter of 3 mm in children younger
than 5 years of age, or 4 mm in the older children [51].
According to the presence or absence of CAA, statistically
significant differences between these 2 groups were found
with respect to the fever duration and 1st IVIG used time
(number of days after the first day of fever) [26,48]. Only
Han Chinese individuals, who account for 98% of the
Taiwanese residents, were considered for recruitment.
This study was approved by the Human Studies Com-
mittee of China Medical University Hospital (CMUH
REC No. DMR101-IRB1-313 (CR-1)).
Consent
The written informed consent was obtained from the pa-
tient’s guardian/parent/next of kin for the publication of
this report and any accompanying images.
SNP genotyping
Fifty-three single nucleotide polymorphisms (SNPs) of
16 genes within the glutamate receptor gene family in-
cluding GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIA1,
GRIA2, GRIA4, GRM1, GRM2, GRM3, GRM4, GRM5,
GRM6, GRM7, and GRM8 were selected from the NCBI
SNP database and HAPMAP website (Tables 2 and 3)
[52]. Selection criteria for including SNPs in the analysis
were a minimum allele frequency of >0.05 in the Han
Chinese population and a Hardy-Weinberg equilibrium
(p >0.05). A summary of information on the SNPs in the
glutamate receptor genes (location, position, rs number,
and genotype) is presented in Table 1. Briefly, genomic
DNA was extracted from peripheral blood leukocytes ac-
cording to the standard protocols (Genomic DNA kit;
Qiagen). SNPs were genotyped using a custom-designed
VeraCode GoldenGate Genotyping Assay System (Illumina);
genotyping was performed as outlined in http://www.
illumina.com/.
Primers and probes were designed and created using
Custom VeraCode GoldenGate Genotyping Assay Sys-
tem software. Genotype calls were automatically gener-
ated using GenCall software version 3.1.3. We assessed
the 8 VeraCode runs individually for intra-plate incon-
sistencies (e.g., variation in fluorescence intensities). Geno-
type cluster plots generated by individual VeraCode and
SAM assays were visually inspected for call quality. Plots
that appeared to be “unusually” clustered (i.e., unlike the
predicted spread in terms of software-generated HWE or
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selecting samples via direct Sanger sequencing for geno-
type confirmation. Samples were sequenced using Big Dye
Terminator v3.1 (AB, Foster City, CA, USA) according to
the manufacturer’s guidelines, and sequenced with an AB
3730 genetic analyzer.Analysis of haplotype blocks
Based on the HAPLOVIEW software, we used the Lewon-
tin D’ measure to estimate the intermarker coefficient of
LD of patients [53]. The confidence interval (CI) of LD
was estimated using a resampling procedure and then
used to construct the haplotype blocks.Statistical analyses
Data are expressed as means ± standard deviation for
continuous variables. Genotypes were obtained by direct
count, followed by allele frequency calculations (Table 1).
χ2 tests were performed to determine the differences in
categorical variables, and the odds ratio and 95% CI
were calculated for the factors under consideration. For-
ward stepwise multivariate regression analyses were also
performed to identify factors that contribute independ-
ently to CAA formation in KD. All statistical analyses
were performed using SPSS (v12.0) for Windows.Additional files
Additional file 1: Figure S1. Search results of single nucleotide
polymorphism (SNP) of rs466013 of the GRIK1 gene used in this study
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=466013).
Above: Genomic location of rs466013 (pointed by red arrows; the NCBI
Assembly database: GRCh37.p10 version). Down: Genomic location of
rs466013 for 6 versions of the NCBI Assembly database (pointed by
red arrows). Figure S2. Search results of single nucleotide
polymorphisms (SNPs) of rs466013, rs425507, rs388700 and rs402280
of the GRIK1 gene used in this study (http://genome.ucsc.edu/cgi-bin/
hgTracks?db=hg18&position=chr21%3A30120300-30129700&hgsid=
370279953_3haDCdtlwLEpPqkcmUFYdaAFYNhx). Above: Genomic
location of the GRIK1 gene. Down: Genomic location of rs466013,
rs425507, rs388700 and rs402280 (pointed by red arrows; the NCBI
Assembly database: NCBI36/hg18 version). Figure S3. GRIK1 mRNA
expression levels in peripheral blood mononuclear cells according to
the GRIK1 SNPs (rs388700 and rs402280) genotypes. The relative GRIK1
expression was detected by quantitative real-time RT-PCR, and expression
from individuals with TT + TA genotypes was compared to that from
individuals with AA genotype. The GRIK1 (NM_000830.3) primer sequences
were 5′-gcggttagagatggatcaaca-3′ (located at nucleotide 2559–2579 of the
transcript (NM_000830.3) and 5′-tcatgaaagcccacatcttct-3′ (located at
nucleotide 2617–2637 of the transcript (NM_000830.3)). The relative
expression levels were expressed as GRIK1 mRNA/ HPRT mRNA ratio.
Figure S4. Venn diagram of 4 GWAS studies. Gene SNPs from 4 GWAS
studies were used for searching for common gene SNPs by using
Venny website (http://bioinfogp.cnb.csic.es/tools/venny/). Figure S5. Venn
diagram of 4 GWAS studies. Gene SNPs from 4 GWAS studies were used for
searching for common gene SNPs by using Venny website (http://bioinfogp.
cnb.csic.es/tools/venny/). Figure S5. Venn diagram of 4 GWAS studies. Gene
SNPs from 4 GWAS studies were used for searching for common gene SNPs
by using Venny website (http://bioinfogp.cnb.csic.es/tools/venny/).Additional file 2: Table S1. Characteristics of GWAS studies for KD
susceptibility included in this meta-analysis. Table S2. Meta-analysis for
previous reported GWAS studies for KD susceptibility.
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